Study of Brexucabtagene Autoleucel (KTE-X19) for the Treatment of Individuals With Relapsed/Refractory B-Cell Malignancies
Clinical trial NCT04162756 · APPROVED_FOR_MARKETING
Trial details
- NCT number
- NCT04162756
- Sponsor
- Kite, A Gilead Company
- Status
- APPROVED_FOR_MARKETING
- Study type
- EXPANDED_ACCESS
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.